Medical - Devices
Compare Stocks
5 / 10Stock Comparison
INGN vs CRVL vs LNTH vs MGRC vs MDT
Revenue, margins, valuation, and 5-year total return — side by side.
Insurance - Brokers
Drug Manufacturers - Specialty & Generic
Rental & Leasing Services
Medical - Devices
INGN vs CRVL vs LNTH vs MGRC vs MDT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Devices | Insurance - Brokers | Drug Manufacturers - Specialty & Generic | Rental & Leasing Services | Medical - Devices |
| Market Cap | $192M | $3.01B | $6.06B | $2.82B | $97.62B |
| Revenue (TTM) | $351M | $941M | $1.55B | $947M | $35.48B |
| Net Income (TTM) | $-25M | $106M | $279M | $155M | $4.61B |
| Gross Margin | 47.6% | 24.2% | 60.5% | 45.9% | 61.9% |
| Operating Margin | -9.1% | 14.5% | 18.8% | 25.5% | 17.9% |
| Forward P/E | — | 33.6x | 17.7x | 18.0x | 13.8x |
| Total Debt | $17M | $28M | $738K | $528M | $28.52B |
| Cash & Equiv. | $104M | $171M | $359M | $295K | $2.22B |
INGN vs CRVL vs LNTH vs MGRC vs MDT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Inogen, Inc. (INGN) | 100 | 18.5 | -81.5% |
| CorVel Corporation (CRVL) | 100 | 258.6 | +158.6% |
| Lantheus Holdings, … (LNTH) | 100 | 677.8 | +577.8% |
| McGrath RentCorp (MGRC) | 100 | 205.6 | +105.6% |
| Medtronic plc (MDT) | 100 | 77.2 | -22.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: INGN vs CRVL vs LNTH vs MGRC vs MDT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Among these 5 stocks, INGN doesn't own a clear edge in any measured category.
CRVL has the current edge in this matchup, primarily because of its strength in growth exposure and sleep-well-at-night.
- Rev growth 12.6%, EPS growth 24.5%, 3Y rev CAGR 11.5%
- Lower volatility, beta 0.42, Low D/E 8.7%, current ratio 1.90x
- 12.6% revenue growth vs LNTH's 0.5%
- Beta 0.42 vs INGN's 1.12, lower leverage
LNTH is the #2 pick in this set and the best alternative if long-term compounding is your priority.
- 42.9% 10Y total return vs MGRC's 402.7%
- 18.0% margin vs INGN's -7.1%
- +15.7% vs CRVL's -47.9%
MGRC is the clearest fit if your priority is valuation efficiency.
- PEG 2.04 vs MDT's 35.17
- Better valuation composite
MDT ranks third and is worth considering specifically for income & stability and defensive.
- Dividend streak 36 yrs, beta 0.42, yield 3.7%
- Beta 0.42, yield 3.7%, current ratio 1.85x
- 3.7% yield, 36-year raise streak, vs MGRC's 1.7%, (3 stocks pay no dividend)
- 175.8% ROA vs INGN's -8.3%, ROIC 6.0% vs -24.4%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 12.6% revenue growth vs LNTH's 0.5% | |
| Value | Better valuation composite | |
| Quality / Margins | 18.0% margin vs INGN's -7.1% | |
| Stability / Safety | Beta 0.42 vs INGN's 1.12, lower leverage | |
| Dividends | 3.7% yield, 36-year raise streak, vs MGRC's 1.7%, (3 stocks pay no dividend) | |
| Momentum (1Y) | +15.7% vs CRVL's -47.9% | |
| Efficiency (ROA) | 175.8% ROA vs INGN's -8.3%, ROIC 6.0% vs -24.4% |
INGN vs CRVL vs LNTH vs MGRC vs MDT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
INGN vs CRVL vs LNTH vs MGRC vs MDT — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
LNTH leads in 2 of 6 categories
MDT leads 1 • INGN leads 0 • CRVL leads 0 • MGRC leads 0 • 3 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
LNTH leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
MDT is the larger business by revenue, generating $35.5B annually — 101.0x INGN's $351M. LNTH is the more profitable business, keeping 18.0% of every revenue dollar as net income compared to INGN's -7.1%. On growth, MDT holds the edge at +8.8% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $351M | $941M | $1.5B | $947M | $35.5B |
| EBITDAEarnings before interest/tax | -$12M | $168M | $347M | $350M | $9.4B |
| Net IncomeAfter-tax profit | -$25M | $106M | $279M | $155M | $4.6B |
| Free Cash FlowCash after capex | -$10M | $69M | $372M | $196M | $5.4B |
| Gross MarginGross profit ÷ Revenue | +47.6% | +24.2% | +60.5% | +45.9% | +61.9% |
| Operating MarginEBIT ÷ Revenue | -9.1% | +14.5% | +18.8% | +25.5% | +17.9% |
| Net MarginNet income ÷ Revenue | -7.1% | +11.2% | +18.0% | +16.4% | +13.0% |
| FCF MarginFCF ÷ Revenue | -2.9% | +7.3% | +24.0% | +20.7% | +15.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | +3.4% | +3.4% | +1.2% | +1.6% | +8.8% |
| EPS Growth (YoY)Latest quarter vs prior year | -20.0% | +2.2% | +76.5% | -4.3% | -11.9% |
Valuation Metrics
Evenly matched — INGN and MGRC each lead in 3 of 7 comparable metrics.
Valuation Metrics
At 18.1x trailing earnings, MGRC trades at a 44% valuation discount to CRVL's 32.0x P/E. Adjusting for growth (PEG ratio), MGRC offers better value at 2.05x vs MDT's 35.17x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $192M | $3.0B | $6.1B | $2.8B | $97.6B |
| Enterprise ValueMkt cap + debt − cash | $106M | $2.9B | $5.7B | $3.3B | $123.9B |
| Trailing P/EPrice ÷ TTM EPS | -8.26x | 31.98x | 27.29x | 18.05x | 21.09x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 33.63x | 17.70x | 18.00x | 13.80x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | 2.05x | 35.17x |
| EV / EBITDAEnterprise value multiple | — | 19.04x | 14.96x | 9.52x | 14.06x |
| Price / SalesMarket cap ÷ Revenue | 0.55x | 3.36x | 3.93x | 2.98x | 2.91x |
| Price / BookPrice ÷ Book value/share | 0.99x | 9.46x | 5.84x | 2.28x | 2.04x |
| Price / FCFMarket cap ÷ FCF | — | 32.83x | 17.11x | 13.33x | 18.83x |
Profitability & Efficiency
Evenly matched — CRVL and LNTH each lead in 4 of 9 comparable metrics.
Profitability & Efficiency
CRVL delivers a 28.1% return on equity — every $100 of shareholder capital generates $28 in annual profit, vs $-13 for INGN. LNTH carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to MDT's 0.59x. On the Piotroski fundamental quality scale (0–9), CRVL scores 8/9 vs LNTH's 5/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -12.9% | +28.1% | +24.3% | +12.8% | +9.4% |
| ROA (TTM)Return on assets | -8.3% | +16.4% | +12.4% | +6.6% | +175.8% |
| ROICReturn on invested capital | -24.4% | +51.3% | +30.6% | +10.5% | +6.0% |
| ROCEReturn on capital employed | -13.3% | +39.5% | +17.1% | +11.3% | +7.5% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 8 | 5 | 6 | 6 |
| Debt / EquityFinancial leverage | 0.09x | 0.09x | 0.00x | 0.43x | 0.59x |
| Net DebtTotal debt minus cash | -$86M | -$143M | -$358M | $528M | $26.3B |
| Cash & Equiv.Liquid assets | $104M | $171M | $359M | $295,000 | $2.2B |
| Total DebtShort + long-term debt | $17M | $28M | $738,000 | $528M | $28.5B |
| Interest CoverageEBIT ÷ Interest expense | — | — | 15.83x | 8.35x | 9.08x |
Total Returns (Dividends Reinvested)
LNTH leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in LNTH five years ago would be worth $43,814 today (with dividends reinvested), compared to $1,074 for INGN. Over the past 12 months, LNTH leads with a +15.7% total return vs CRVL's -47.9%. The 3-year compound annual growth rate (CAGR) favors MGRC at 10.0% vs INGN's -16.0% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +5.9% | -11.0% | +38.3% | +9.9% | -20.0% |
| 1-Year ReturnPast 12 months | +10.6% | -47.9% | +15.7% | +4.1% | -5.5% |
| 3-Year ReturnCumulative with dividends | -40.8% | -16.1% | -1.9% | +33.1% | -6.3% |
| 5-Year ReturnCumulative with dividends | -89.3% | +49.6% | +338.1% | +50.3% | -29.2% |
| 10-Year ReturnCumulative with dividends | -85.7% | +270.4% | +4289.6% | +402.7% | +24.3% |
| CAGR (3Y)Annualised 3-year return | -16.0% | -5.7% | -0.6% | +10.0% | -2.1% |
Risk & Volatility
Evenly matched — CRVL and LNTH each lead in 1 of 2 comparable metrics.
Risk & Volatility
CRVL is the less volatile stock with a 0.42 beta — it tends to amplify market swings less than INGN's 1.12 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. LNTH currently trades 98.1% from its 52-week high vs CRVL's 49.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.12x | 0.42x | 0.45x | 0.83x | 0.42x |
| 52-Week HighHighest price in past year | $9.13 | $117.22 | $94.86 | $128.41 | $106.33 |
| 52-Week LowLowest price in past year | $5.34 | $44.83 | $47.25 | $94.99 | $75.91 |
| % of 52W HighCurrent price vs 52-week peak | +76.9% | +49.9% | +98.1% | +89.3% | +71.6% |
| RSI (14)Momentum oscillator 0–100 | 60.5 | 58.3 | 69.9 | 52.8 | 29.2 |
| Avg Volume (50D)Average daily shares traded | 289K | 200K | 872K | 211K | 7.9M |
Analyst Outlook
MDT leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: INGN as "Buy", LNTH as "Buy", MGRC as "Buy", MDT as "Buy". Consensus price targets imply 270.4% upside for INGN (target: $26) vs 6.7% for LNTH (target: $99). For income investors, MDT offers the higher dividend yield at 3.65% vs MGRC's 1.70%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | — | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $26.00 | — | $99.25 | $140.00 | $109.50 |
| # AnalystsCovering analysts | 11 | — | 17 | 5 | 49 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | +1.7% | +3.7% |
| Dividend StreakConsecutive years of raises | — | 1 | 0 | 36 | 36 |
| Dividend / ShareAnnual DPS | — | — | — | $1.94 | $2.78 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +1.3% | +5.0% | 0.0% | +3.3% |
LNTH leads in 2 of 6 categories (Income & Cash Flow, Total Returns). MDT leads in 1 (Analyst Outlook). 3 tied.
INGN vs CRVL vs LNTH vs MGRC vs MDT: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is INGN or CRVL or LNTH or MGRC or MDT a better buy right now?
For growth investors, CorVel Corporation (CRVL) is the stronger pick with 12.
6% revenue growth year-over-year, versus 0. 5% for Lantheus Holdings, Inc. (LNTH). McGrath RentCorp (MGRC) offers the better valuation at 18. 1x trailing P/E (18. 0x forward), making it the more compelling value choice. Analysts rate Inogen, Inc. (INGN) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — INGN or CRVL or LNTH or MGRC or MDT?
On trailing P/E, McGrath RentCorp (MGRC) is the cheapest at 18.
1x versus CorVel Corporation at 32. 0x. On forward P/E, Medtronic plc is actually cheaper at 13. 8x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: McGrath RentCorp wins at 2. 04x versus Medtronic plc's 35. 17x.
03Which is the better long-term investment — INGN or CRVL or LNTH or MGRC or MDT?
Over the past 5 years, Lantheus Holdings, Inc.
(LNTH) delivered a total return of +338. 1%, compared to -89. 3% for Inogen, Inc. (INGN). Over 10 years, the gap is even starker: LNTH returned +42. 9% versus INGN's -85. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — INGN or CRVL or LNTH or MGRC or MDT?
By beta (market sensitivity over 5 years), CorVel Corporation (CRVL) is the lower-risk stock at 0.
42β versus Inogen, Inc. 's 1. 12β — meaning INGN is approximately 169% more volatile than CRVL relative to the S&P 500. On balance sheet safety, Lantheus Holdings, Inc. (LNTH) carries a lower debt/equity ratio of 0% versus 59% for Medtronic plc — giving it more financial flexibility in a downturn.
05Which is growing faster — INGN or CRVL or LNTH or MGRC or MDT?
By revenue growth (latest reported year), CorVel Corporation (CRVL) is pulling ahead at 12.
6% versus 0. 5% for Lantheus Holdings, Inc. (LNTH). On earnings-per-share growth, the picture is similar: Inogen, Inc. grew EPS 44. 1% year-over-year, compared to -32. 7% for McGrath RentCorp. Over a 3-year CAGR, LNTH leads at 18. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — INGN or CRVL or LNTH or MGRC or MDT?
McGrath RentCorp (MGRC) is the more profitable company, earning 16.
6% net margin versus -6. 5% for Inogen, Inc. — meaning it keeps 16. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MGRC leads at 25. 9% versus -8. 7% for INGN. At the gross margin level — before operating expenses — MDT leads at 65. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is INGN or CRVL or LNTH or MGRC or MDT more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, McGrath RentCorp (MGRC) is the more undervalued stock at a PEG of 2. 04x versus Medtronic plc's 35. 17x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, Medtronic plc (MDT) trades at 13. 8x forward P/E versus 33. 6x for CorVel Corporation — 19. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for INGN: 270. 4% to $26. 00.
08Which pays a better dividend — INGN or CRVL or LNTH or MGRC or MDT?
In this comparison, MDT (3.
7% yield), MGRC (1. 7% yield) pay a dividend. INGN, CRVL, LNTH do not pay a meaningful dividend and should not be held primarily for income.
09Is INGN or CRVL or LNTH or MGRC or MDT better for a retirement portfolio?
For long-horizon retirement investors, Medtronic plc (MDT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
42), 3. 7% yield). Both have compounded well over 10 years (MDT: +24. 3%, INGN: -85. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between INGN and CRVL and LNTH and MGRC and MDT?
These companies operate in different sectors (INGN (Healthcare) and CRVL (Financial Services) and LNTH (Healthcare) and MGRC (Industrials) and MDT (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: INGN is a small-cap quality compounder stock; CRVL is a small-cap quality compounder stock; LNTH is a small-cap quality compounder stock; MGRC is a small-cap quality compounder stock; MDT is a mid-cap income-oriented stock. MGRC, MDT pay a dividend while INGN, CRVL, LNTH do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.